Sonata vs. Dayvigo
See how Sonata and Dayvigo compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Sonata is a short-acting nonbenzodiazepine hypnotic best suited for trouble falling asleep, while Dayvigo's orexin-blocking mechanism is approved for both falling asleep and staying asleep.
Both carry a boxed warning for complex sleep behaviors like sleep-walking or sleep-driving and are Schedule IV controlled substances with dependence potential.
Sonata has decades of generic use and a lower price, while Dayvigo is newer, brand-only, and backed by 12-month trial data on sustained effect.
Sonata vs. Dayvigo Drug Summary
Sonata
Sonata (zaleplon) is a nonbenzodiazepine sedative-hypnotic approved for short-term treatment of insomnia in adults. It is taken as an oral capsule at bedtime, and its very short half-life means some people can take it in the middle of the night if at least 4 hours of sleep time remain.
Dayvigo
Dayvigo (lemborexant) is a dual orexin receptor antagonist approved for insomnia in adults who have trouble falling asleep, staying asleep, or both. It is taken as a single oral tablet each night, usually starting at the lowest effective dose.
Sonata vs. Dayvigo Side Effects
Sonata
Dayvigo
Sonata vs. Dayvigo Dosage
Sonata
Dayvigo
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once nightly | At the start |
| Maximum dose | 20 mg once nightly | If needed |
| Dose changes | 2 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once nightly | At the start |
| Maximum dose | 10 mg once nightly | If needed |
| Dose changes | 1 increase | As tolerated |
Sonata
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once nightly | At the start |
| Maximum dose | 20 mg once nightly | If needed |
| Dose changes | 2 increases | As tolerated |
Dayvigo
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once nightly | At the start |
| Maximum dose | 10 mg once nightly | If needed |
| Dose changes | 1 increase | As tolerated |
Sonata vs. Dayvigo Indications
Sonata
Sonata is FDA-approved only for short-term insomnia treatment in adults who have trouble falling asleep. It is not intended for long-term nightly use or for children and adolescents under 18.
Short-term treatment of insomnia in adults
Helps people fall asleep faster
Not approved for chronic nightly use
Not approved for patients under 18
Dayvigo
Dayvigo is FDA-approved for adults with insomnia marked by trouble falling asleep, staying asleep, or both. Its efficacy has been studied over a full year, supporting more sustained nightly use than some other hypnotics.
Insomnia with difficulty falling and/or staying asleep
Supported by 12-month trial data
Not approved for narcolepsy
Not approved for pediatric patients
Sonata vs. Dayvigo Pros and Cons
Sonata
Sonata's ultra-short half-life makes it useful for occasional middle-of-the-night waking, and its metabolism through aldehyde oxidase means fewer drug interactions than many other hypnotics. It is generic and widely available, but it is approved only for short-term use and may not help much with staying asleep through the night.
Pros
Very short half-life allows middle-of-night dosing if 4+ hours remain
Fewer drug interactions due to non-CYP metabolism
Roughly $25 to $115 per month generic, before insurance
Decades of real-world use since its 1999 approval
Cons
Approved for short-term use only, not chronic nightly treatment
Contains tartrazine dye, a risk for allergic reactions in sensitive people
Short duration may not help with staying asleep through the night
Requires lower dose in elderly, liver impairment, or with cimetidine
Dayvigo
Dayvigo's orexin-blocking mechanism is approved for both falling asleep and staying asleep, with 12-month trial data supporting continued use without rebound insomnia. It has no generic version yet, so out-of-pocket costs run higher, and it requires caution with certain CYP3A-affecting medications.
Pros
Approved for both falling asleep and staying asleep
12-month trial data show sustained effect without rebound insomnia
Orexin-blocking mechanism differs from GABA-based hypnotics
Simple two-dose regimen with no titration needed
Cons
Roughly $135 to $400 per month, with no generic version yet
Must avoid strong or moderate CYP3A inhibitors/inducers
Carries a warning for possible worsening of depression or suicidal thoughts
Less real-world history, approved more recently in 2019
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.